Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Showing results for "1"

News & Events

Netball star on the ball

West Coast Fever netball player Verity Charles is proof that living with T1D doesn't mean your sporting dream has to take a backseat to your condition

News & Events

Diabetes education at home trial

We recently ran a study to compare the traditional model of care with a family-friendly, slower-paced, home-based alternative.

Research

Respiratory allergen from house dust mite is present in human milk and primes for allergic sensitization in a mouse model of asthma

These data highlight that antigen administration to the neonate through the oral route may contribute to child allergic sensitization and have important...

RESP-ACT

The aim of RESP-ACT is to reduce these children’s respiratory hospital admissions and visits to Emergency Department, and to help them and their families to have as the best possible quality of life.

Research

“If you build it, they will come”: the convergence of funding, research and collaboration in paediatric brain cancer clinical trials

Each year, approximately 1000 children in Australia and New Zealand, aged 0–14 years, are diagnosed with cancer. Despite paediatric cancer accounting for less than 1% of all cancer cases, the impact on their families and communities is profound and disproportionate.

Research

Interferon β-1a ring prophylaxis to reduce household transmission of SARS-CoV-2: a cluster randomised clinical trial

Accumulating evidence indicates that an early, robust type 1 interferon (IFN) response to SARS-CoV-2 is important in determining COVID-19 outcomes, with an inadequate IFN response associated with disease severity. Our objective was to examine the prophylactic potential of IFN administration to limit viral transmission.

Research

Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia

KMT2A-rearranged acute lymphoblastic leukemia (ALL) in infants is an aggressive disease with 3-year event-free survival below 40%. Most relapses occur during treatment, with two thirds occurring within 1 year and 90% within 2 years after diagnosis. Outcomes have not improved in recent decades despite intensification of chemotherapy.

Research

Acute Lymphoblastic Leukemia in Infants: A Distinctive, High-Risk Subtype of Childhood Acute Lymphoblastic Leukemia

Acute lymphoblastic leukemia (ALL) in infants younger than 1 year of age is an aggressive, high-risk subtype of childhood ALL. Infant ALL with KMT2A-r is characteristically poorly responsive to chemotherapy and hematopoietic stem cell transplantation. New strategies, such as molecularly targeted therapies and immunotherapies, are in development and show promise in preclinical models and early phase studies.

Research

Identification and genetic determination of an early life risk disposition for depressive disorder:

Progress in psychiatric genetics has been slow despite evidence of high heritability for most mental disorders

News & Events

Introducing the Rio Tinto Children's Diabetes Centre, A JDRF Global Centre of Excellence

Introducing the Rio Tinto Children's Diabetes Centre: A JDRF Global Centre of Excellence